Viral replication rate regulates clinical outcome and CD8 T Cell responses during highly pathogenic H5N1 influenza virus infection in mice

PLoS Pathogens

Volumn 6, Issue 10, 2010, Pages

  Hatta, Yasuko ^a   Hershberger, Karen ^a   Shinya, Kyoko ^b   Proll, Sean C ^c   Dubielzig, Richard R ^a   Hatta, Masato ^a   Katze, Michael G ^c   Kawaoka, Yoshihiro ^a,d   Suresh, M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; OSELTAMIVIR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; LUNG INFECTION; MOUSE; NONHUMAN; PATHOGENICITY; STEADY STATE; SURVIVAL TIME; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DOGS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; LUNG DISEASES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PROGNOSIS; VIRUS REPLICATION;

AVES; MUS; ORTHOMYXOVIRIDAE;

EID: 78449265281     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001139     Document Type: Article

References (49)

1. Graham MB, Braciale TJ (1997) Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 186: 2063-2068.
2. Topham DJ, Tripp RA, Doherty PC (1997) CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 159: 5197-5200.
3. Woodland DL (2003) Cell-mediated immunity to respiratory virus infections. Curr Opin Immunol 15: 430-435.
4. Epstein SL, Lo CY, Misplon JA, Bennink JR (1998) Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 160: 322-327.
5. Lawrence CW, Braciale TJ (2004) Activation, differentiation, and migration of naive virus-specific CD8+ T cells during pulmonary influenza virus infection. J Immunol 173: 1209-1218.
6. Lawrence CW, Ream RM, Braciale TJ (2005) Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol 174: 5332-5340.
7. Bender BS, Croghan T, Zhang L, Small PA, Jr. (1992) Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 175: 1143-1145.
8. Lee BO, Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Makris M, et al. (2005) CD4 T cell-independent antibody response promotes resolution of primary influenza infection and helps to prevent reinfection. J Immunol 175: 5827-5838.
9. La Gruta NL, Kedzierska K, Stambas J, Doherty PC (2007) A question of selfpreservation: immunopathology in influenza virus infection. Immunol Cell Biol 85: 85-92.
10. Moskophidis D, Kioussis D (1998) Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med 188: 223-232.
11. Enelow RI, Mohammed AZ, Stoler MH, Liu AN, Young JS, et al. (1998) Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest 102: 1653-1661.
12. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203-1207.
13. Hatta M, Gao P, Halfmann P, Kawaoka Y (2001) Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293: 1840-1842.
14. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, et al. (1998) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279: 393-396.
15. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, et al. (1999) A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73: 5903-5911.
16. Katz JM, Lu X, Tumpey TM, Smith CB, Shaw MW, et al. (2000) Molecular correlates of influenza A H5N1 virus pathogenesis in mice. J Virol 74: 10807-10810.
17. Jackson D, Hossain MJ, Hickman D, Perez DR, Lamb RA (2008) A new influenza virus virulence determinant: the NS1 protein four C-terminal residues modulate pathogenicity. Proc Natl Acad Sci U S A 105: 4381-4386.
18. Seo SH, Hoffmann E, Webster RG (2002) Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 8: 950-954.
19. Szretter KJ, Gangappa S, Belser JA, Zeng H, Chen H, et al. (2009) Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol 83: 5825-5834.
20. Opferman JT, Korsmeyer SJ (2003) Apoptosis in the development and maintenance of the immune system. Nat Immunol 4: 410-415.
21. Marsden VS, Strasser A (2003) Control of apoptosis in the immune system: Bcl- 2, BH3-only proteins and more. Annu Rev Immunol 21: 71-105.
22. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, et al. (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51: 123-129.
23. Gillissen A, Hoffken G (2002) Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment. Med Microbiol Immunol 191: 165-168.
24. Schirmer P, Holodniy M (2009) Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opin Drug Saf 8: 357-371.
25. Yen HL, Monto AS, Webster RG, Govorkova EA (2005) Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 192: 665-672.
26. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 107: 882-887.
27. Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, et al. (1998) Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351: 472-477.
28. Cox NJ, Subbarao K (2000) Global epidemiology of influenza: past and present. Annu Rev Med 51: 407-421.
29. Cilloniz C, Shinya K, Peng X, Korth MJ, Proll SC, et al. (2009) Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog 5: e1000604.
30. Neumann G, Chen H, Gao GF, Shu Y, Kawaoka Y H5N1 influenza viruses: outbreaks and biological properties. Cell Res 20: 51-61.
31. Legge KL, Braciale TJ (2005) Lymph node dendritic cells control CD8+ T cell responses through regulated FasL expression. Immunity 23: 649-659.
32. Fornek JL, Gillim-Ross L, Santos C, Carter V, Ward JM, et al. (2009) A singleamino- acid substitution in a polymerase protein of an H5N1 influenza virus is associated with systemic infection and impaired T-cell activation in mice. J Virol 83: 11102-11115.
33. Zhou J, Law HK, Cheung CY, Ng IH, Peiris JS, et al. (2006) Functional tumor necrosis factor-related apoptosis-inducing ligand production by avian influenza virus-infected macrophages. J Infect Dis 193: 945-953.
34. Meng XW, Lee SH, Dai H, Loegering D, Yu C, et al. (2007) Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 282: 29831-29846.
35. Werneburg NW, Guicciardi ME, Bronk SF, Kaufmann SH, Gores GJ (2007) Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem 282: 28960-28970.
36. Han J, Goldstein LA, Gastman BR, Rabinowich H (2006) Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 281: 10153-10163.
37. McGill J, Van Rooijen N, Legge KL (2008) Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. J Exp Med 205: 1635-1646.
38. Tumpey TM, Lu X, Morken T, Zaki SR, Katz JM (2000) Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol 74: 6105-6116.
39. Li Q, Skinner PJ, Ha SJ, Duan L, Mattila TL, et al. (2009) Visualizing antigenspecific and infected cells in situ predicts outcomes in early viral infection. Science 323: 1726-1729.
40. Budhu S, Loike JD, Pandolfi A, Han S, Catalano G, et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med 207: 223-235, S221-224.
41. Daidoji T, Koma T, Du A, Yang CS, Ueda M, et al. (2008) H5N1 avian influenza virus induces apoptotic cell death in mammalian airway epithelial cells. J Virol 82: 11294-11307.
42. Badovinac VP, Porter BB, Harty JT (2004) CD8+ T cell contraction is controlled by early inflammation. Nat Immunol 5: 809-817.
43. Cilloniz C, Pantin-Jackwood MJ, Ni C, Goodman AG, Peng X, et al. Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J Virol 84: 7613-7624.
44. Kacergius T, Ambrozaitis A, Deng Y, Gravenstein S (2006) Neuraminidase inhibitors reduce nitric oxide production in influenza virus-infected and gamma interferon-activated RAW 264.7 macrophages. Pharmacol Rep 58: 924-930.
45. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, et al. (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286: 1735-1738.
46. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, et al. (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148: 1198-1215.
47. Fung-Leung WP, Schilham MW, Rahemtulla A, Kundig TM, Vollenweider M, et al. (1991) CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell 65: 443-449.
48. Martinez X, Kreuwel HT, Redmond WL, Trenney R, Hunter K, et al. (2005) CD8+ T cell tolerance in nonobese diabetic mice is restored by insulindependent diabetes resistance alleles. J Immunol 175: 1677-1685.
49. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202: 637-650.